{"id":"W4311668626","doi":"10.1038/s41591-022-02102-9","title":"Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; Université de Montréal; St. Boniface Hospital; Montreal Heart Institute","funders":"National Heart, Lung, and Blood Institute; Relypsa; National Medical Research Council; Respicardia; American Regent; Vifor Pharma; Daiichi-Sankyo; University of Glasgow; Bayer HealthCare; Pfizer; Moderna; Impulse Dynamics; Sarepta Therapeutics; Ionis Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; Sanofi Pasteur; Kowa Company; Celladon Corporation; Defense Acquisition Program Administration; Boston Scientific Corporation; Medical Research Council; Verily Life Sciences; Brigham and Women's Hospital; Heart Failure Society of America; Esperion Therapeutics; Alnylam Pharmaceuticals; Novo Nordisk; MyoKardia; Servier; Bayer; Gilead Sciences; Cytokinetics; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Amgen; Sanofi; American Heart Association","keywords":"Dapagliflozin; Ejection fraction; Heart failure; Medicine; Internal medicine; Cardiology; Fraction (chemistry); Chemistry; Diabetes mellitus; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003563936,0.0001270177,0.0004646969,0.0004924118,0.0000771773,0.000003354753,0.00009635634,0.00008196031,0.001005765],"category_scores_gemma":[0.00007887476,0.00007019889,0.0001228362,0.002181406,0.00006165931,0.00004097928,0.00006151468,0.0006253122,8.958475e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001949141,"about_ca_system_score_gemma":0.00004288961,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001380615,"about_ca_topic_score_gemma":0.0003282864,"domain_scores_codex":[0.998679,0.00009626264,0.0002492466,0.0002516127,0.00057536,0.0001485043],"domain_scores_gemma":[0.9992885,0.00007582529,0.0001349045,0.0003874539,0.00007017863,0.00004313832],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2001737,0.006286841,0.4529069,0.0003980025,0.02244079,0.0001773103,0.003193809,0.001905133,0.04458398,0.001984122,0.2503095,0.01563997],"study_design_scores_gemma":[0.1494254,0.008105461,0.4129716,0.0001926801,0.01459413,0.00001333452,0.003826266,0.002781293,0.003067006,0.00006175728,0.4046558,0.0003052905],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9824933,0.0006030582,0.00003173091,0.01227778,0.0004940481,0.001454511,0.000007189843,0.00003199887,0.002606376],"genre_scores_gemma":[0.9965768,0.000009831071,0.0001575996,0.00117318,0.000220227,0.00009390189,0.00006859276,0.00001138567,0.001688473],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1543463,"threshold_uncertainty_score":0.9999074,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008697059207868693,"score_gpt":0.2606465506638542,"score_spread":0.2519494914559856,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}